Harmony Biosciences Holdings Inc. (HRMY) Social Stream

Featured Post From StockTwits About HRMY

$HRMY Company is exceeding analyst earnings projections so far this year. Next year EPS are projected by analysts to be 10X higher. If they execute continued growth at that rate this stock will have a much high price target from analysts before year end. Harmony has 2 ongoing clinical trials in different orphan neurological disorders with somnolence (PWS and MD), testing pitolisant for clinical benefit to expand the indications for it's use. Regulatory approval for these additional patient populations will offer new indications for prescribing without competition from the drugs that Harmony competes with in narcolepsy and cataplexy since competitors have not done clinical trials in patients with those conditions. Approvals for these indications will raise potential revenues and earnings even higher than currently projected. This company has tremendous growth potential. At the current price, it's a good long term hold into 2022.